



## (51) International Patent Classification:

*C07K 19/00* (2006.01)      *A61P 37/04* (2006.01)  
*A61K 39/155* (2006.01)    *C07K 14/135* (2006.01)  
*A61K 39/385* (2006.01)    *C12N 15/44* (2006.01)  
*A61P 31/14* (2006.01)    *C12N 15/62* (2006.01)

## (21) International Application Number:

PCT/CA2009/001021

## (22) International Filing Date:

17 July 2009 (17.07.2009)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/081,888      18 July 2008 (18.07.2008)      US

(71) Applicant (for all designated States except US): **ID BIOMEDICAL CORPORATION OF QUEBEC** [CA/CA]; 525 Cartier Ouest, Laval, Québec H7V 3S8 (CA).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **BLAIS, Normand** [CA/CA]; 525 Cartier Ouest, Laval, Québec, H7V 3S8 (CA). **RHEAULT, Patrick** [CA/CA]; 525 Cartier Ouest, Laval, Québec, H7V 3S8 (CA).

(74) Agents: **D'IORIO, Hélène** et al.; Gowling Lafleur Henderson LLP, 1 Place Ville Marie, 37th Floor, Montréal, Québec H3B 3P4 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


## Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: CHIMERIC RESPIRATORY SYNCYTIAL VIRUS POLYPEPTIDE ANTIGENS

FIG. 1



(57) Abstract: Chimeric respiratory syncytial virus (RSV) polypeptide antigens are provided. The disclosed polypeptides include a first amino acid sequence comprising an F2 domain uncleavably joined to an F1 domain of a Respiratory Syncytial Virus (RSV) Fusion (F) protein polypeptide; and a second amino acid sequence comprising a portion of an RSV Attachment (G) protein polypeptide comprising an immunologically dominant epitope. The disclosure also provides nucleic acids that encode, and pharmaceutical compositions that contain, the chimeric RSV polypeptides, as well as methods for their production and use.